CervoMed Inc

NASDAQ:CRVOUnited States

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.

Contact Information

Headquarters

20 Park Plaza, Suite 424BOSTON, MA, United States 02116

Phone

617-744-4400

Fax

434-220-0722

Executives

Chairman of the Board

Joshua Boger

President, Chief Executive Officer, Director

John Alam

Chief Financial Officer, General Counsel, Corporate Secretary

William Elder

Chief Operating Officer, Director

Robert Cobuzzi

Senior Vice President - Clinical Development

Kelly Blackburn